South Korea · Delayed Price · Currency is KRW L&K Biomed Statistics
Total Valuation
L&K Biomed has a market cap or net worth of KRW 207.97 billion. The enterprise value is 213.06 billion.
| Market Cap | 207.97B |
| Enterprise Value | 213.06B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
L&K Biomed has 20.76 million shares outstanding. The number of shares has increased by 15.02% in one year.
| Current Share Class | 20.76M |
| Shares Outstanding | 20.76M |
| Shares Change (YoY) | +15.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.78% |
| Owned by Institutions (%) | 0.34% |
| Float | 18.10M |
Valuation Ratios
The trailing PE ratio is 111.90.
| PE Ratio | 111.90 |
| Forward PE | n/a |
| PS Ratio | 5.20 |
| PB Ratio | 5.62 |
| P/TBV Ratio | 4.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.88, with an EV/FCF ratio of -16.29.
| EV / Earnings | 105.12 |
| EV / Sales | 5.33 |
| EV / EBITDA | 32.88 |
| EV / EBIT | 62.64 |
| EV / FCF | -16.29 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.65.
| Current Ratio | 1.66 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | 3.72 |
| Debt / FCF | -1.84 |
| Interest Coverage | 1.00 |
Financial Efficiency
Return on equity (ROE) is 5.81% and return on invested capital (ROIC) is 3.64%.
| Return on Equity (ROE) | 5.81% |
| Return on Assets (ROA) | 2.68% |
| Return on Invested Capital (ROIC) | 3.64% |
| Return on Capital Employed (ROCE) | 7.78% |
| Revenue Per Employee | 416.51M |
| Profits Per Employee | 21.11M |
| Employee Count | 60 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 0.29 |
Taxes
In the past 12 months, L&K Biomed has paid 751.48 million in taxes.
| Income Tax | 751.48M |
| Effective Tax Rate | 27.22% |
Stock Price Statistics
The stock price has increased by +39.47% in the last 52 weeks. The beta is 1.59, so L&K Biomed's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +39.47% |
| 50-Day Moving Average | 9,071.00 |
| 200-Day Moving Average | 7,298.55 |
| Relative Strength Index (RSI) | 58.14 |
| Average Volume (20 Days) | 281,764 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&K Biomed had revenue of KRW 39.99 billion and earned 2.03 billion in profits. Earnings per share was 89.54.
| Revenue | 39.99B |
| Gross Profit | 32.81B |
| Operating Income | 3.40B |
| Pretax Income | 2.76B |
| Net Income | 2.03B |
| EBITDA | 6.48B |
| EBIT | 3.40B |
| Earnings Per Share (EPS) | 89.54 |
Balance Sheet
The company has 13.35 billion in cash and 24.08 billion in debt, giving a net cash position of -10.73 billion or -517.20 per share.
| Cash & Cash Equivalents | 13.35B |
| Total Debt | 24.08B |
| Net Cash | -10.73B |
| Net Cash Per Share | -517.20 |
| Equity (Book Value) | 37.03B |
| Book Value Per Share | 2,140.34 |
| Working Capital | 24.07B |
Cash Flow
In the last 12 months, operating cash flow was -11.09 billion and capital expenditures -1.99 billion, giving a free cash flow of -13.08 billion.
| Operating Cash Flow | -11.09B |
| Capital Expenditures | -1.99B |
| Free Cash Flow | -13.08B |
| FCF Per Share | -630.03 |
Margins
Gross margin is 82.06%, with operating and profit margins of 8.51% and 5.07%.
| Gross Margin | 82.06% |
| Operating Margin | 8.51% |
| Pretax Margin | 6.90% |
| Profit Margin | 5.07% |
| EBITDA Margin | 16.21% |
| EBIT Margin | 8.51% |
| FCF Margin | n/a |
Dividends & Yields
L&K Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.02% |
| Shareholder Yield | -15.02% |
| Earnings Yield | 0.97% |
| FCF Yield | -6.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
L&K Biomed has an Altman Z-Score of 2.46 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.46 |
| Piotroski F-Score | 5 |